Clinical experiment designed to assess clinical efficacy targeting PSP in human. Primary outcome: Map the spatial-temporal progression of tau pathology in PSP, identifying primary initiation sites i
Description
Tau Pathology Initiation Zone Identification
Background and Rationale
Progressive Supranuclear Palsy (PSP) is a devastating tauopathy characterized by abnormal accumulation of 4R-tau protein in neurons and glia. While PSP presents with heterogeneous clinical phenotypes, the underlying pathological mechanisms driving disease initiation and progression remain poorly understood. Current neuropathological studies suggest that tau pathology follows stereotyped anatomical patterns, but the precise initiation sites and spreading mechanisms have not been systematically validated in living patients. This study leverages advanced neuroimaging techniques including tau-PET using [18F]PI-2620 tracer, high-resolution structural MRI, and diffusion tensor imaging to identify and validate tau pathology initiation zones in PSP patients. The central hypothesis posits that 4R-tau pathology begins in specific brainstem nuclei, particularly the sublaterodorsal nucleus and cholinergic tegmental nuclei, before propagating through anatomically connected networks to subcortical and cortical regions....
Tau Pathology Initiation Zone Identification
Background and Rationale
Progressive Supranuclear Palsy (PSP) is a devastating tauopathy characterized by abnormal accumulation of 4R-tau protein in neurons and glia. While PSP presents with heterogeneous clinical phenotypes, the underlying pathological mechanisms driving disease initiation and progression remain poorly understood. Current neuropathological studies suggest that tau pathology follows stereotyped anatomical patterns, but the precise initiation sites and spreading mechanisms have not been systematically validated in living patients. This study leverages advanced neuroimaging techniques including tau-PET using [18F]PI-2620 tracer, high-resolution structural MRI, and diffusion tensor imaging to identify and validate tau pathology initiation zones in PSP patients. The central hypothesis posits that 4R-tau pathology begins in specific brainstem nuclei, particularly the sublaterodorsal nucleus and cholinergic tegmental nuclei, before propagating through anatomically connected networks to subcortical and cortical regions. This longitudinal study will recruit 120 PSP patients across different clinical phenotypes (PSP-Richardson syndrome, PSP-parkinsonism, PSP-frontal) and 40 age-matched controls. Participants will undergo comprehensive clinical assessments, neuropsychological testing, and multimodal neuroimaging at baseline, 6, 12, and 24 months. Advanced image analysis will employ voxel-wise statistical mapping, network-based connectivity analysis, and machine learning algorithms to identify tau pathology patterns and predict clinical progression. The innovation lies in combining cutting-edge tau-PET imaging with high-resolution brainstem-focused MRI protocols and longitudinal design to capture early pathological changes in living patients. This approach will validate postmortem neuropathological findings in vivo and potentially identify biomarkers for early diagnosis and disease monitoring. Success will fundamentally advance our understanding of PSP pathogenesis and support development of targeted therapeutic interventions by defining critical windows and anatomical targets for disease-modifying treatments.
This experiment directly tests predictions arising from the following hypotheses:
LRP1-Dependent Tau Uptake Disruption
HSP90-Tau Disaggregation Complex Enhancement
Synaptic Vesicle Tau Capture Inhibition
Tau-Independent Microtubule Stabilization via MAP6 Enhancement
Noradrenergic-Tau Propagation Blockade
Experimental Protocol
Phase 1 (Months 1-6): Recruit 120 PSP patients meeting MDS-PSP criteria across three phenotypes (PSP-RS n=50, PSP-P n=35, PSP-F n=35) and 40 healthy controls matched for age, sex, and education. Conduct baseline assessments including PSP Rating Scale, MoCA, Frontal Assessment Battery, and motor evaluations. Phase 2 (Months 1-30): Perform multimodal neuroimaging at baseline, 6, 12, and 24 months. Tau-PET imaging using [18F]PI-2620 (370 MBq IV injection, 90-110 minute post-injection acquisition on Siemens Biograph mCT). High-resolution 3T MRI including T1-weighted MPRAGE, T2-weighted FLAIR, and diffusion tensor imaging (64 directions, b=1000 s/mm²). Brainstem-focused sequences with 0.5mm isotropic resolution targeting midbrain and pontine nuclei. Phase 3 (Months 7-36): Image processing using FreeSurfer 7.0 for cortical parcellation, FSL for diffusion analysis, and SUVR quantification using cerebellar cortex reference region. Voxel-wise statistical analysis using SPM12, identifying regions with tau burden >1.3 SUVR threshold. Network-based analysis using graph theory metrics to map connectivity patterns. Phase 4 (Months 31-48): Integrate longitudinal tau-PET and clinical data using mixed-effects models. Machine learning classification (random forest, SVM) to identify predictive patterns. Validate findings through cross-sectional postmortem correlation study (n=25 brain specimens). Statistical analysis includes ANOVA for group comparisons, Pearson correlations for clinical-imaging relationships, and survival analysis for progression outcomes using R statistical software.
Expected Outcomes
Sublaterodorsal and cholinergic tegmental nuclei will show 2-3 fold higher tau burden (SUVR >1.8) compared to cortical regions (SUVR <1.4) at baseline in early-stage PSP patients (p<0.001).
Longitudinal tau accumulation will follow a rostral-caudal gradient, with brainstem regions showing 15-20% annual increase versus 5-10% in cortical areas over 24 months.
PSP-Richardson syndrome will demonstrate more widespread brainstem tau pathology (affecting >70% of midbrain nuclei) compared to PSP-parkinsonism (40-50% involvement) at baseline.
Machine learning models will achieve >85% accuracy in predicting clinical phenotype based on baseline tau distribution patterns in brainstem and basal ganglia regions.
Diffusion tensor imaging will reveal reduced fractional anisotropy (>20% decrease) in white matter tracts connecting high tau-burden brainstem nuclei to subcortical targets.
Clinical progression rates will correlate strongly (r>0.7) with baseline tau burden in sublaterodorsal nucleus, with each 0.1 SUVR increase predicting 2-point faster PSP Rating Scale deterioration annually.
Success Criteria
Demonstrate statistically significant (p<0.01) higher baseline tau burden in hypothesized brainstem initiation sites compared to cortical regions across ≥80% of PSP patients
Achieve >80% sensitivity and >85% specificity in identifying brainstem tau initiation zones using automated image analysis algorithms validated against expert radiological assessment
Establish significant correlation (r>0.6, p<0.001) between baseline brainstem tau burden and clinical progression rates measured by PSP Rating Scale over 24-month follow-up
Successfully differentiate PSP clinical phenotypes with >80% classification accuracy using tau distribution patterns, particularly in brainstem and subcortical regions
Complete longitudinal follow-up in ≥85% of enrolled participants with <10% missing imaging data across all timepoints
Validate neuroimaging findings through postmortem correlation showing >75% concordance between in vivo tau-PET signals and neuropathological tau burden measurements in brainstem nuclei
TARGET GENE
PSP
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Map the spatial-temporal progression of tau pathology in PSP, identifying primary initiation sites in brainstem nuclei and establishing tau burden thresholds for early disease detection with >85% diagnostic accuracy.
Phase 1 (Months 1-6): Recruit 120 PSP patients meeting MDS-PSP criteria across three phenotypes (PSP-RS n=50, PSP-P n=35, PSP-F n=35) and 40 healthy controls matched for age, sex, and education. Conduct baseline assessments including PSP Rating Scale, MoCA, Frontal Assessment Battery, and motor evaluations. Phase 2 (Months 1-30): Perform multimodal neuroimaging at baseline, 6, 12, and 24 months. Tau-PET imaging using [18F]PI-2620 (370 MBq IV injection, 90-110 minute post-injection acquisition on Siemens Biograph mCT). High-resolution 3T MRI including T1-weighted MPRAGE, T2-weighted FLAIR, and diffusion tensor imaging (64 directions, b=1000 s/mm²). Brainstem-focused sequences with 0.5mm isotropic resolution targeting midbrain and pontine nuclei.
...
Phase 1 (Months 1-6): Recruit 120 PSP patients meeting MDS-PSP criteria across three phenotypes (PSP-RS n=50, PSP-P n=35, PSP-F n=35) and 40 healthy controls matched for age, sex, and education. Conduct baseline assessments including PSP Rating Scale, MoCA, Frontal Assessment Battery, and motor evaluations. Phase 2 (Months 1-30): Perform multimodal neuroimaging at baseline, 6, 12, and 24 months. Tau-PET imaging using [18F]PI-2620 (370 MBq IV injection, 90-110 minute post-injection acquisition on Siemens Biograph mCT). High-resolution 3T MRI including T1-weighted MPRAGE, T2-weighted FLAIR, and diffusion tensor imaging (64 directions, b=1000 s/mm²). Brainstem-focused sequences with 0.5mm isotropic resolution targeting midbrain and pontine nuclei. Phase 3 (Months 7-36): Image processing using FreeSurfer 7.0 for cortical parcellation, FSL for diffusion analysis, and SUVR quantification using cerebellar cortex reference region. Voxel-wise statistical analysis using SPM12, identifying regions with tau burden >1.3 SUVR threshold. Network-based analysis using graph theory metrics to map connectivity patterns. Phase 4 (Months 31-48): Integrate longitudinal tau-PET and clinical data using mixed-effects models. Machine learning classification (random forest, SVM) to identify predictive patterns. Validate findings through cross-sectional postmortem correlation study (n=25 brain specimens). Statistical analysis includes ANOVA for group comparisons, Pearson correlations for clinical-imaging relationships, and survival analysis for progression outcomes using R statistical software.
Expected Outcomes
Sublaterodorsal and cholinergic tegmental nuclei will show 2-3 fold higher tau burden (SUVR >1.8) compared to cortical regions (SUVR <1.4) at baseline in early-stage PSP patients (p<0.001).
Longitudinal tau accumulation will follow a rostral-caudal gradient, with brainstem regions showing 15-20% annual increase versus 5-10% in cortical areas over 24 months.
PSP-Richardson syndrome will demonstrate more widespread brainstem tau pathology (affecting >70% of midbrain nuclei) compared to PSP-parkinsonism (40-50% involvement) at baseline.
Machine learning models will achieve >85% accuracy in
...
Sublaterodorsal and cholinergic tegmental nuclei will show 2-3 fold higher tau burden (SUVR >1.8) compared to cortical regions (SUVR <1.4) at baseline in early-stage PSP patients (p<0.001).
Longitudinal tau accumulation will follow a rostral-caudal gradient, with brainstem regions showing 15-20% annual increase versus 5-10% in cortical areas over 24 months.
PSP-Richardson syndrome will demonstrate more widespread brainstem tau pathology (affecting >70% of midbrain nuclei) compared to PSP-parkinsonism (40-50% involvement) at baseline.
Machine learning models will achieve >85% accuracy in predicting clinical phenotype based on baseline tau distribution patterns in brainstem and basal ganglia regions.
Diffusion tensor imaging will reveal reduced fractional anisotropy (>20% decrease) in white matter tracts connecting high tau-burden brainstem nuclei to subcortical targets.
Clinical progression rates will correlate strongly (r>0.7) with baseline tau burden in sublaterodorsal nucleus, with each 0.1 SUVR increase predicting 2-point faster PSP Rating Scale deterioration annually.
Success Criteria
Demonstrate statistically significant (p<0.01) higher baseline tau burden in hypothesized brainstem initiation sites compared to cortical regions across ≥80% of PSP patients
Achieve >80% sensitivity and >85% specificity in identifying brainstem tau initiation zones using automated image analysis algorithms validated against expert radiological assessment
Establish significant correlation (r>0.6, p<0.001) between baseline brainstem tau burden and clinical progression rates measured by PSP Rating Scale over 24-month follow-up
Successfully differentiate PSP clinical phenotypes with >80% cl
...
Demonstrate statistically significant (p<0.01) higher baseline tau burden in hypothesized brainstem initiation sites compared to cortical regions across ≥80% of PSP patients
Achieve >80% sensitivity and >85% specificity in identifying brainstem tau initiation zones using automated image analysis algorithms validated against expert radiological assessment
Establish significant correlation (r>0.6, p<0.001) between baseline brainstem tau burden and clinical progression rates measured by PSP Rating Scale over 24-month follow-up
Successfully differentiate PSP clinical phenotypes with >80% classification accuracy using tau distribution patterns, particularly in brainstem and subcortical regions
Complete longitudinal follow-up in ≥85% of enrolled participants with <10% missing imaging data across all timepoints
Validate neuroimaging findings through postmortem correlation showing >75% concordance between in vivo tau-PET signals and neuropathological tau burden measurements in brainstem nuclei